e-learning
resources
Virtual 2020
Pre-Congress Content
Clinical and laboratory pharmacology in asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Assessment of biological therapy in asthma-obesity phenotype
E. Makarova (Chelyabinsk, Russian Federation), G. Ignatova (Chelyabinsk, Russian Federation)
Source:
Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Session:
Clinical and laboratory pharmacology in asthma
Session type:
E-poster session
Number:
1408
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Makarova (Chelyabinsk, Russian Federation), G. Ignatova (Chelyabinsk, Russian Federation). Assessment of biological therapy in asthma-obesity phenotype. 1408
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score.
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021
Fitness for radical treatment modalities: efficient functional assessment, improving fitness and fitness-adapted therapy concepts including the elderly
Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy
Year: 2017
Immunoproteasome function as a potential biomarker for asthma severity and response to therapy
Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease
Year: 2021
Clinical and pathophysiological features of asthma phenotypes
Source: Annual Congress 2013 –Asthma at the bedside
Year: 2013
The utility of HLA-DQB302 as a genetic marker to predict the effect of aspirin desensitization on lung function of patients with aspirin exacerbated respiratory disease
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
Proof of concept study to evaluate step down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma
Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Year: 2010
Menopausal asthma: a new biological phenotype?
Source: Annual Congress 2009 - One size (does not) fit all: phenotyping and controlling asthma
Year: 2009
Identification of molecular pathways in distinct asthma phenotypes identified in ADEPT
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015
Identifying patients with severe asthma that will be benefit from biological therapy
Source: Virtual Congress 2020 – Rethinking asthma
Year: 2020
Physical activity pattern of severe asthmatic patients treated with biological therapy.
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
Individual dynamic of inflammatory markers as indicators of COPD treatment effectiveness
Source: International Congress 2014 – COPD: points to ponder
Year: 2014
Monitoring the inflammatory heterogeneity in asthma with multiple biomarkers for multidimensional endotyping
Source: International Congress 2017 – "Alarming" immunological patterns in asthma
Year: 2017
Novel biomarker more strongly associated with tuberculosis treatment outcome than conventional or genotypic methods
Source: International Congress 2015 – Science and biomarkers in TB
Year: 2015
Interference RNA as a new tool and possible future therapy for inflammatory lung disease
Source: Lung Science Conference 2005 - Evidence-based medicine for respiratory disease with special emphasis on inflammatory processes
Year: 2005
Functional independence measure scale in patients with lung cancer after chemotherapy
Source: Annual Congress 2008 - Functionality and metabolism in rehabilitation candidates
Year: 2008
Lung hypertension: developmental mechanisms and assesment therapeutic action efficiency
Source: Annual Congress 2009 - Pulmonary circulation II
Year: 2009
Assessment of thyroid function tests in COPD phenotypes
Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD
Year: 2020
Is the association between physical activity and lung function due to reverse causation? An application of exploratory and causal approaches
Source: International Congress 2019 – Tuberculosis epidemiology, bronchiectasis, other infections and spirometry
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept